Moderna shares climbed 3% even after Citigroup downgraded the stock to Sell, citing high valuation following a 222% rise since positive melanoma vaccine trial results. The market seems optimistic about Moderna's personalized cancer vaccine pipeline, especially the upcoming full data expected in late October at a European oncology conference. Citigroup respects the science but warns that the current stock price already reflects the melanoma trial success, limiting further gains without new evidence. Investors will watch for broader cancer treatment potential in the full data to justify Moderna's valuation.
Moderna's market cap stands at $81.23 billion as of Oct 01, 2026 22:11 WIB, with a 1-day gain of 3.00% on Pluang, reflecting continued investor interest despite Citigroup's downgrade. BioNTech trades near $98.12 with a slight dip of 0.18%, while Pfizer holds a strong dividend yield of 6.03% and a market cap of $162.55 billion, showing more stable investor demand. The typical hold time for Moderna on Pluang is 59 days, indicating moderate-term investor confidence amid ongoing developments in its cancer vaccine pipeline.
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology eff...
Moderna shares surged 6% amid a broader market rotation from AI and tech stocks into healthcare, outperforming peers BioNTech and Pfizer. This rally is supported by positive clinical data from August showing Moderna's personalized mRNA cancer vaccine...
Moderna's stock has surged over 650% this year due to excitement around its personalized cancer vaccine showing promising trial results. Despite this rally, analyst price targets remain much lower than the current share price, suggesting the stock ma...
